Personalis

PSNL

Market cap $521M

Overview Fund Activity

5.87 USD

-0.06

1.01%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

5.98

+0.11

1.87%

1 day

-1.01%

5 days

7.9%

1 month

21.03%

3 months

-8.99%

6 months

54.47%

Year to date

-6.38%

1 year

6.34%

5 years

-75.06%

10 years

-79.4%

About: Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Employees: 229

Healthcare Diagnostics & Research

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

106% more capital invested

Capital invested by funds: $192M [Q1] → $397M (+$204M) [Q2]

36% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 25

6.32% more ownership

Funds ownership: 62.12% [Q1] → 68.45% (+6.32%) [Q2]

6% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 31

1% more funds holding

Funds holding: 104 [Q1] → 105 (+1) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

6% less call options, than puts

Call options by funds: $753K | Put options by funds: $799K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$8.5

45% upside

Avg. target

$8.5

45% upside

High target

$8.5

45% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Swayampakula Ramakanth

$8.5

Buy

Reiterated

8 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about PSNL published over the past 30 days

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis' new Senior Vice President, Chief Information Officer under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awa.

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale Cancer Center for a clinical trial titled “A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE),” a novel ctDNA-guided study aimed at improving outcomes in patients w.

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate that Personalis' highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer (NSCLC) receiving neoadjuvant therapy. The findings, which will be p.

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis to Participate in Upcoming Investor Conferences

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the following conferences: Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel in New York, NY Lake Street 9th Annual Best Ideas Growth Conference on Thursday, September 11, 2025, at the Yale Club in New York, NY About Personalis, Inc. A.

Personalis to Participate in Upcoming Investor Conferences

Zacks Investment Research

Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)

The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)

Zacks Investment Research

After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)

Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)

Zacks Investment Research

All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy

Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

The Motley Fool

Personalis (PSNL) Q2 Revenue Falls 24%

Personalis (PSNL) Q2 Revenue Falls 24%

Personalis (PSNL) Q2 Revenue Falls 24%

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Personalis, Inc. (NASDAQ:PSNL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Aaron L. Tachibana - CFO & COO Christopher M.

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™